A growing body of clinical evidence indicates that while anti-PD-1 and anti-PD-L1 therapies yield favorable outcomes in dMMR/MSI-H cancers, they are less effective in cold pMMR/MSS colorectal cancer. This evidence concerns the gene PDCD1 and cancer.